Terns Pharmaceuticals, Inc. Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

TERN

Rank in Stocks #3571
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Share Price
$52.95
Last synced: 2026-05-15
Market Cap
$4.77B
Change (1 day)
0.00%
Change (1 year)
529.61%
Country
US
Trade Terns Pharmaceuticals, Inc. (TERN)

Category

Healthcare
Stock split history for Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. stock (symbol: TERN) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 19, 2026.
One TERN share bought prior to Oct 19, 2026 would equal to 0 TERN shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL